Clinical trials: Lipoprotein(a)
Hypercholesterolaemia
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
This is a study to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naïve patients. Laroprovstat is a small molecule that reduces the amount of LDL-C in the blood.
- Trial name
- NCT07619131
- Testing
- Laroprovstat, Rosuvastatin 1, Rosuvastatin 2
- Where
- 152 sites in United States, Bulgaria and 9 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Dyslipidemia
Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels
The purpose of this study is to evaluate safety of JTT-705 and to demonstrate efficacy of JTT-705 compared with placebo when co-administered with atorvastatin 20 mg in patients with low HDL
- Trial name
- NCT00689442
- Testing
- JTT-705 600 mg and atorvastatin 20 mg
- Where
- Netherlands
- Volunteers
- 105 people
- Sponsor
- Akros Pharma Inc.
Metabolic Syndrome X
A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism
Agents that increase HDL-C via reverse cholesterol transport could provide a new therapeutic option for the prevention of atherosclerotic cardiovascular disease.
- Trial name
- NCT00327002
- Testing
- LY518674
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia
Patterns of Inclisiran Use in the Real World: An Analysis of US Databases
This was a retrospective observational cohort study of patients who initiated inclisiran, alirocumab, or evolocumab in a real-world setting in the United States.
- Trial name
- NCT07023445
- Where
- United States
- Volunteers
- 37,688 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Disease
Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy
The objective of this study is to determine the acute and chronic [4-week] effects of a high-DHA fish oil supplement on fasting and post-prandial (post-meal) biomarkers of cardiovascular disease risk, in adults on Statin therapy.
- Trial name
- NCT01690312
- Testing
- Fish Oil
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Nutrasource Pharmaceutical and Nutraceutical Services, Inc.
Blood Pressure, Low Density Lipoprotein Cholesterol Level
Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol
The purpose of this study is to evaluate the benefit and tolerability of IQP-AS-118 on the systolic and diastolic blood pressure (BP) and to explore the effects on parameters of lipid metabolism in subjects with elevated BP and…
- Trial name
- NCT02871362
- Testing
- IQP-AS-118
- Where
- Germany
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Coronary Artery Disease, Diabetes
Benefits of Eggs in Combination With a Plant-based Diet
The main objective of the study is to demonstrate that the inclusion of eggs to a plant-based diet will not increase the risk for heart disease but will increase the concentration of lutein and zeaxanthin, two important…
- Conditions
- Coronary Artery Disease, Diabetes, Metabolic Syndrome
- Trial name
- NCT04234334
- Testing
- Consume 2 eggs with spinach per day, Egg Subsitute with spinach per day
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Connecticut
HIV-1 Infection
Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate
This study is being done with people with HIV infection who have low levels of HDL-C. HDL-C is a type of "good" cholesterol. People with low HDL-C have a higher risk of heart disease and may have problems with how their blood…
- Trial name
- NCT01426438
- Testing
- Niacin, Aspirin, Fenofibrate
- Where
- 14 sites in United States
- Volunteers
- 99 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
Extracts of Amla, Walnut Leaf, Red Yeast Rice and Olive in Cardiovascular Prevention
The aim of this study is to evaluate whether the use of a commercially available standardized combination preparation (Cholesfytol NG®), containing extracts of amla, walnut leaf, red yeast rice and olive, in individuals with…
- Trial name
- AmWaRO (NCT06333158)
- Testing
- Cholesfytol NG
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- Nina Hermans
Hyperlipidemias, Hypertension
Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab
The purpose of this study is to evaluate the effectiveness of Olostar Tablet on blood pressure and lipid profiles, obtain safety-related information for subgroups that failed to participate in the clinical trials, and to evaluate…
- Trial name
- NCT05411887
- Testing
- Rosuvastatin, Olmesartan Medoxomil
- Where
- South Korea
- Volunteers
- 2,845 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hypercholesterolemia, Familial
Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with placebo, on percent change from baseline in LDL-C in adults with heterozygous familial…
- Trial name
- RUTHERFORD (NCT01375751)
- Testing
- Evolocumab
- Volunteers
- 168 people
- Sponsor
- Amgen
Coronary Artery Disease
Lp(a) With CCTA Assessed Parameters and Clinical Outcomes
Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular events, although the underlying mechanism remains unclear. This study evaluated the relationship between Lp(a) and high-risk attributes (HRA) by coronary computed…
- Trial name
- CHART-ACCORD (NCT05323227)
- Testing
- Coronary CTA
- Where
- China
- Volunteers
- 378 people
- Sponsor
- Shanghai Zhongshan Hospital
Cardiovascular Disease, Diabetes
The Effects of Natural Versus Man-Made Trans Fatty Acids on Lipoprotein Profiles: A Pilot Study
The purpose of this study is to test the effects of natural vs. man-made trans fatty acids (trans fats) on blood cholesterol.
- Conditions
- Cardiovascular Disease, Diabetes, Dyslipidemia
- Trial name
- NCT00535886
- Testing
- Man-made Trans FA, Natural Trans FA, Oleic Acid
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Healthy Participants
SP16 SERPIN-like Peptide Administration in Healthy Individuals
This study is a randomized, double-blind, placebo-controlled Phase 1 Clinical Trial of 24 healthy individuals to test the safety, tolerability and pharmacokinetics of a single subcutaneous administration of Serpin Peptide 16…
- Trial name
- NCT03651089
- Testing
- SP16
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Serpin Pharma, LLC
Kidney Transplant, Familial Hypercholesterolaemia
Cardiovascular Risk in Children With Chronic Conditions Study
Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels.
- Conditions
- Kidney Transplant, Familial Hypercholesterolaemia, Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM)
- Trial name
- CR3C (NCT07086989)
- Where
- 3 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Semmelweis University
Healthy Volunteer
Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C
This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study of orally administered lomitapide in healthy male Japanese and Caucasian subjects with elevated LDL-C.
- Trial name
- NCT01760187
- Testing
- lomitapide
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Aegerion Pharmaceuticals, Inc.
POAF, Atrial Fibrillation (AF)
Association of Lipoprotein(a) With Postoperative Atrial Fibrillation
About one in three patients who undergo open-heart surgery develop an irregular heart rhythm called postoperative atrial fibrillation (POAF).
- Trial name
- LPa and POAF (NCT07737444)
- Volunteers
- 20 people
- Sponsor
- Anthony Tang
Cholesterol; Metabolic Disorder, Lipoproteinemia
Kinetic Study of Lp(a) and PCSK9 in Humans
The aim is to study the relationship between lipoprotein(a) [Lp(a)] and PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) in humans with a kinetic study of lipoproteins in patients with dramatic increase of Lp(a) and controls.
- Trial name
- HuLaUP (NCT04247048)
- Testing
- infusion of tracer [5,5,5-2H3] -L-leucine
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Nantes University Hospital
Inclisiran Formulation
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
The purpose of this study is to compare safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the currently marketed formulation of inclisiran with a new formulation containing polysorbate 80 (PS80), after a…
- Trial name
- NCT07626281
- Testing
- Inclisiran formulation containing PS80, Currently marketed inclisiran formulation
- Where
- 6 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Diseasse
Low-Density Lipoprotein Cholesterol-targeting Statin Therapy Versus the Intensity-based Statin Therapy in Patients With Coronary Artery Disease
To compare clinical safety \& efficacy of fixed-high potent statin therapy (according to 2013 ACC/AHA guideline) vs. targeted LDL-C goal statin therapy (LDL<70mg/dL) for secondary prevention.
- Trial name
- LODESTAR (NCT02579499)
- Testing
- fixed high potent statin therapy, targeted LDL-C goal statin
- Where
- South Korea
- Volunteers
- 4,400 people
- Sponsor
- Yonsei University